Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Advances in Cancer Immunotherapy: New Insights, Novel Checkpoints
share announcement

Advances in Cancer Immunotherapy: New Insights, Novel Checkpoints

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 1682

Special Issue Editors

Dr. Konstantinos Syrigos

E-Mail Website
Guest Editor
Third Department of Internal Medicine, Sotiria Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece
Interests: cancer; lung cancer; immunotherapy; immune-related adverse events
Special Issues, Collections and Topics in MDPI journals
Dr. Ioannis Vathiotis

E-Mail Website
Guest Editor
Third Department of Internal Medicine, Sotiria Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece
Interests: cancer; lung cancer; head and neck cancer; immunotherapy; immune-related adverse events
Special Issues, Collections and Topics in MDPI journals
Dr. Andriani Charpidou

E-Mail Website
Guest Editor
Third Department of Internal Medicine, Sotiria Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece
Interests: cancer; lung cancer; treatment; immunotherapy; vaccine

Special Issue Information

Dear Colleagues,

The incorporation of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors into the treatment algorithm of different tumor types has revolutionized cancer care. However, only a subgroup of patients benefit from the currently approved immune therapies. The human tumor microenvironment is governed by the crosstalk between multiple immune regulatory molecules and/or pathways. Thus, in the majority of cases, the elicitation of deep and sustained antitumor responses may require more than the manipulation of a sole immune checkpoint.

This Special Issue aims to provide a comprehensive collection of review articles on the key advances in, and emerging targets for, cancer immunotherapy.

We look forward to receiving your contributions.

Dr. Konstantinos Syrigos
Dr. Ioannis Vathiotis
Dr. Andriani Charpidou
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • treatment
  • immunotherapy
  • vaccine

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

27 pages, 1541 KiB  
Review
Clinical Applications of Combined Immunotherapy Approaches in Gastrointestinal Cancer: A Case-Based Review
by Yesim Eralp and Utku Ates
Vaccines 2023, 11(10), 1545; https://doi.org/10.3390/vaccines11101545 - 29 Sep 2023
Cited by 1 | Viewed by 1306
Abstract
Malignant neoplasms arising from the gastrointestinal (GI) tract are among the most common types of cancer with high mortality rates. Despite advances in treatment in a small subgroup harboring targetable mutations, the outcome remains poor, accounting for one in three cancer-related deaths observed [...] Read more.
Malignant neoplasms arising from the gastrointestinal (GI) tract are among the most common types of cancer with high mortality rates. Despite advances in treatment in a small subgroup harboring targetable mutations, the outcome remains poor, accounting for one in three cancer-related deaths observed globally. As a promising therapeutic option in various tumor types, immunotherapy with immune checkpoint inhibitors has also been evaluated in GI cancer, albeit with limited efficacy except for a small subgroup expressing microsatellite instability. In the quest for more effective treatment options, energetic efforts have been placed to evaluate the role of several immunotherapy approaches comprising of cancer vaccines, adoptive cell therapies and immune checkpoint inhibitors. In this review, we report our experience with a personalized dendritic cell cancer vaccine and cytokine-induced killer cell therapy in three patients with GI cancers and summarize current clinical data on combined immunotherapy strategies. Full article
(This article belongs to the Special Issue Advances in Cancer Immunotherapy: New Insights, Novel Checkpoints)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop